AstraZeneca agrees to sell commercial rights to Atacand to Cheplapharm Arzneimittel GmbH
LONDON: AstraZeneca has agreed to sell the commercial rights to Atacand (candesartan cilexetil) and Atacand Plus (a fixed-dose combination of candesartan cilexetil and hydrochlorothiazide) in around 70 countries globally to Cheplapharm Arzneimittel GmbH (Cheplapharm). Cheplapharm will pay AstraZeneca a total of $400m in non-contingent consideration, of which the present value will be recognised as Other…